Immupharma PLC Incanthera - Comm'l Skincare Deal/GBP1M Fundraise (0696X)
18 Dezember 2023 - 8:15AM
UK Regulatory
TIDMIMM
RNS Number : 0696X
Immupharma PLC
18 December 2023
18 December 2023
ImmuPharma PLC
("ImmuPharma" or the "Company")
Incanthera Secures Commercial Skincare Deal & GBP1M
Fundraise
ImmuPharma PLC (LSE AIM: IMM), the specialist drug discovery and
development company, is delighted to highlight the announcement
issued this morning by Incanthera plc ("Incanthera"), the
dermatology and oncology specialist, in which ImmuPharma currently
holds a 12.7% shareholding.
Within the announcement, Incanthera announces a significant
commercial skincare deal with Marionnaud (part of the A.S. Watson
Group) initially across Europe and further roll outs in Asia. It
confirmed that this deal is expected to generate significant
revenues and profitability for Incanthera, in 2024 and beyond.
In conjunction Incanthera announces that it has concluded a
successful fundraise of GBP1,000,000, with new and existing
institutional investors which was oversubscribed, and is priced at
GBP0.07, a premium of 11.1% to the mid-market price at the close of
trading on Friday 15 December 2023.
Incanthera trades on Aquis Stock Exchange ("AQSE") under the
ticker (AQSE:INC). For full details of the announcement, please
visit Incanthera's website:
https://incanthera.com/investors/regulatory-news/ .
Commenting on Incanthera's announcement, Dr Tim Franklin, COO of
ImmuPharma said : "As a major shareholder in Incanthera, we are
delighted with this significant milestone, which highlights the
enormous opportunities within Incanthera's revolutionary skincare
range."
For further information please contact:
ImmuPharma PLC ( www.immupharma.com ) +44 (0) 207 206 2650
Dr Tim Franklin, COO
Lisa Baderoon, Head of Investor Relations + 44 (0) 7721 413496
SPARK Advisory Partners Limited (NOMAD)
Neil Baldwin +44 (0) 203 36 8 3550
Stanford Capital Partners (Joint Broker)
Patrick Claridge, Bob Pountney +44 (0) 203 650 3650/51
SI Capital (Joint Broker)
Nick Emerson +44 (0) 1483 413500
Notes to Editors
About ImmuPharma PLC
ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical
company that discovers and develops peptide-based therapeutics. The
Company's portfolio includes novel peptide therapeutics for
autoimmune diseases and anti-infectives. The lead program, P140
(Lupuzor(TM)), is a first-in class autophagy immunomodulator for
the treatment of Lupus and preclinical analysis suggest therapeutic
activity for many other autoimmune diseases that share the same
autophagy mechanism of action.
For additional information about ImmuPharma please visit
www.immupharma.co.uk
ImmuPharma's LEI (Legal Entity Identifier) code :
213800VZKGHXC7VUS895.
About Incanthera plc
Incanthera is a specialist company focused on innovative
technologies in dermatology and oncology. It seeks to identify and
develop innovative solutions to current clinical, commercially
relevant unmet needs, utilising new technology from leading
specialists and academic institutions as well as its in-house
development team.
Incanthera originated from the Institute of Cancer Therapeutics
("ICT") at the University of Bradford. Incanthera's strategy is to
develop each candidate in its portfolio from initial acquisition or
discovery to securing its future through commercially valuable
partnerships at the earliest opportunity in its development
pathway.
For more information on Incanthera please visit:
www.incanthera.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
MSCUBORRORUUAUA
(END) Dow Jones Newswires
December 18, 2023 02:15 ET (07:15 GMT)
Immupharma (AQSE:IMM.GB)
Historical Stock Chart
Von Nov 2024 bis Dez 2024
Immupharma (AQSE:IMM.GB)
Historical Stock Chart
Von Dez 2023 bis Dez 2024